228 related articles for article (PubMed ID: 34907171)
1. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
[TBL] [Abstract][Full Text] [Related]
2. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
3. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
4. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
5. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
6. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
7. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
8. A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Ryan JM; Mittal P; Menoret A; Svedova J; Wasser JS; Adler AJ; Vella AT
Cancer Immunol Immunother; 2018 Apr; 67(4):605-613. PubMed ID: 29327109
[TBL] [Abstract][Full Text] [Related]
9. Could OX40 agonist antibody promote activation of the anti-tumor immune response in gastric cancer?
Martins MR; Santos RLD; Jatahy KDN; Matta MCD; Batista TP; Júnior JIC; Begnami MDFS; Torres LC
J Surg Oncol; 2018 Apr; 117(5):840-844. PubMed ID: 29529339
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
11. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
12. The effect of aging on OX40 agonist-mediated cancer immunotherapy.
Ruby CE; Weinberg AD
Cancer Immunol Immunother; 2009 Dec; 58(12):1941-7. PubMed ID: 19288101
[TBL] [Abstract][Full Text] [Related]
13. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
15. Radiation Augments the Local Anti-Tumor Effect of
Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
Front Immunol; 2021; 12():763888. PubMed ID: 34868010
[TBL] [Abstract][Full Text] [Related]
16. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
18. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
19. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
